Vonoprazan Fumarate, also known as TAK438, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. TAKECAB provides a strong and sustained acid secretion inhibitory effect.
Synonyms:
TAK-438;
1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine,(E)-4-oxopent-2-enoic acid;
Potassium Channel Inhibitors Related Prodcuts:
Glimepiride; Gliclazide; Almitrine dimesylate; JNJ303; Dofetilide; Dronedarone HCl; Mitiglinide Calcium; Glyburide; ML213